Staging ::: VER CORREOS
Acceder

Farmas USA

134K respuestas
Farmas USA
85 suscriptores
Farmas USA
Página
2.263 / 17.016
#18099

Re: Farmas USA

alguien se atreve con un corto? jeje!!
edito. con 1000dolares le sacas 24000 flipante!!

#18100

Re: Farmas USA

IB a dado de alta el servicio de noticias gratuito para clientes, en mi plataforma a empezado hoy ,en especial para las que tienes en cartera,mandaron un email creo que el viernes comunicandolo,S2

#18101

Re: Farmas USA

Hoy he entrado de nuevo en AMRN

En este articulo la ponen bastante bien

Analysts at MKM Partners said FDA draft guidance for generic Lovaza, stating that the Omega-3-Acid Ethyl Esters (Lovaza) USP monograph defines the active pharmaceutical ingredient (API) for Lovaza as composed of seven individual omega-3-acid ethyl ester components, does not preclude Amarin's (NASDAQ: AMRN) Vascepa from qualifying for NCE exclusivity.

"While EPA, the main component of Vascepa, is included as one of the seven API components, we do not think that this precludes Vascepa from qualifying for NCE exclusivity," analyst Jon LeCroy, M.D. states. "The case on whether to grant Vascepa NCE status is not cut and dry and the FDA has twice delayed its formal determination of NCE status."

LeCroy continues to expect the FDA to grant Vascepa NCE status in the next update of the Orange Book, expected around October 12.

MKM Partners maintained its Buy rating and price target of $21.50.

For an analyst ratings summary and ratings history on Amarin Corporation click here. For more ratings news on Amarin Corporation click here.

Shares of Amarin are down 6 percent Monday to $12.57.

#18103

Re: Farmas USA

A mi por suerte me ha pillado sin cash, que sino te acompaño con toda seguridad.´
Ánimo chavalote.

#18104

Re: Farmas USA

He dejado esta mañana orden a 2.75 y me ha entrado!!! .... Pero ya voy perdiendo ;( CTIC